Irish subsidiary of global medical device group; specialist in minimally invasive cardiac and pulmonary intervention device development and commercialization.
Teleflex Medical Europe is the Irish subsidiary of Teleflex Inc., a global medical device manufacturer specializing in minimally invasive clinical intervention products. Their H2020 participation reveals a focused applied R&D function — contributing device expertise and commercialization capability to EU-funded projects targeting cardiac arrhythmia and lung cancer treatment. In both projects, they bring the industrial product development side: translating clinical innovations into manufacturable, market-ready medical devices. Their involvement in Innovation Actions (rather than Research Actions) confirms their role as an industry partner bridging research prototypes toward commercialization.
LAA-START (2019–2022) targeted left atrial appendage electrical isolation using bio-photonic confirmation, a catheter-based cardiac procedure area aligned with Teleflex's broader vascular device portfolio.
TABLA (2020–2023) developed transbronchial microwave ablation as a lung cancer treatment, with Teleflex contributing medical device development and commercialization expertise.
Both projects are classified as Innovation Actions — funding schemes explicitly designed for late-stage development and market preparation, which is where an industrial partner like Teleflex adds most value.
TABLA's focus on microwave thermal ablation represents a technically distinct but strategically adjacent expansion from the optical/photonic approach used in LAA-START.
Their two projects run nearly simultaneously (2019 and 2020 starts), so this is not a sequential pivot but rather a parallel exploration of two distinct minimally invasive device categories. The earlier project (LAA-START) sits in cardiac electrophysiology — a more established field with defined clinical pathways. The more recent entry (TABLA) moves into interventional oncology via thermal ablation, a faster-growing segment with broader commercial potential. Taken together, the direction is clear: Teleflex is positioning itself in bronchoscopic and catheter-based energy delivery systems across both cardiac and pulmonary indications.
Teleflex appears to be broadening from cardiac-only device work into interventional pulmonology and oncology, suggesting growing interest in catheter and bronchoscope-delivered energy therapies as a platform capability.
Teleflex consistently joins as a participant rather than taking the coordinator role, which fits their profile as a large industrial company that contributes product development and market access expertise rather than project management overhead. With only 8 unique partners across 2 projects, their consortium footprint is small and targeted — they appear to select specific technology partners rather than building broad networks. This suggests they are selective, outcome-driven collaborators who engage when a project aligns directly with their commercialization pipeline.
Teleflex Medical Europe has collaborated with 8 unique partners across 5 countries, indicating a deliberately focused European network rather than broad geographic diversification. Their collaboration pattern reflects targeted partnership selection tied to specific device development projects rather than a hub-and-spoke research network.
As the Irish manufacturing and commercial arm of a global medical device group, Teleflex Medical Europe brings something most academic or SME consortium members cannot: direct access to regulatory affairs capability, manufacturing scale-up, and established distribution channels across European markets. For any consortium developing an interventional medical device, having Teleflex as an industrial partner significantly strengthens the commercialization narrative — which is exactly what Innovation Action evaluators look for. Their niche focus on minimally invasive, catheter- and bronchoscope-delivered devices makes them a precise fit for projects in cardiac EP, pulmonology, and thermal oncology.
